Share
A new observational trial has started, evaluating immune responses in patients with lymphoid cancers to COVID-19 vaccines.
The Prospective Observational Study Evaluating COVID-19 Vaccine Immune Responses in Lymphoid Cancer (PROSECO) trial aims to recruit 680 patients who will provide blood samples before and after vaccination so that clinicians can study their B and T cell responses.
Lymphoid cancers or lymphomas, originate from lymphocytes, a type of immune system cell. PROSECO is looking to recruit patient with all types of non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukaemia.
The trial will run from seven sites across the UK – the centres in Southampton, Oxford, Nottingham, Leicester, Portsmouth, Norwich are now open and another is being set up in Newcastle. Patients with lymphoid cancer are being approached by clinicians and invited to attend but patients who live in areas of participating centres are encouraged to approach their clinicians if the